2020 has been a year like no other for me and my scientists. COVID-19 changed our scientific, clinical, and personal lives. At the NeuroNetwork, we began one of the nation’s most active centers of the study and treatment of COVID-19, as well as continuing our life-saving work in ALS, the complications of diabetes, and Alzheimer’s disease.
Here is our story of this most challenging year, and I hope you will write or email me yours. Your support is what could give this story a happy ending, and we hope you will consider a gift this year to keep our research in the NeuroNetwork moving forward.
January 1: We launched the NeuroNetwork for Emerging Therapies and formalized collaborations with 40 scientists in Michigan, across the U.S.A., and in Australia, Denmark, England, India, and Israel.
March 9: I returned to Ann Arbor from Washington D.C. after having a briefing on COVID-19, and frankly was in shock as I grasped the enormity of what I had learned. Our team developed a strategy to shift our efforts to data analyses and research publications, in anticipation that the virus would suspend our research and lab operations.